|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
|
|---|---|---|---|
| Cash | |||
| Accounts receivable | |||
| Accrued interest due | |||
| Inventory | |||
| Supplements | |||
| Biologics | |||
| Prepaid Inventory | |||
| Total inventory | |||
| Prepaid expenses | |||
| Undeposited funds | |||
| Total Current Assets | |||
| Note receivable | |||
| Intangible assets – trademarks, net of amortization | |||
| Investment in non-consolidated entity | |||
| Receivable on sale of inventory asset | |||
| Loans to clinics | |||
| Deposits | |||
| Fixed assets, net of depreciation | |||
| Finance lease, net | |||
| Right of use asset - operating lease, net | |||
| Total Non Current Assets | |||
| Total Assets | |||
| Accounts payable | |||
| Payroll liabilities | |||
| Accrued interest – related party | |||
| Deferred revenue | |||
| Line of credit | |||
| Operating | |||
| Finance | |||
| Total Current Liabilities | |||
| Total Non Current Liabilities | |||
| Total Liabilities | |||
| Preferred Stock, Value, Issued | |||
| Special 2022 Series A Preferred Stock | |||
| Series A Preferred Stock | |||
| Series C Preferred Stock | |||
| Common Stock, Value, Issued | |||
| Common Class A | |||
| Common Class B | |||
| Shares to be issued | |||
| Additional paid-in capital | |||
| Accumulated deficit | |||
| Total Stockholders' Equity (Deficit) | |||
| Total Liabilities and Stockholders’ Equity (Deficit) |
Loading...
